Clinical Trials Browser

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06859424 2026-03-17

ACCELERATE

Phase 2 Recruiting

358 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Lymphoma, Myeloproliferative Disorders, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Clinical Trials

ACCESS

ACCELERATE

MK-1026-003

BRUIN-CLL-314

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

TITANium

OPTIMIZE

Soundtrack-E

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

BaseCAR-01

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

CD22 Redirected Autologous T Cells for ALL

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

CARPASCIO

TRICAR-ALL

OPAL

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

ARQ 531-101

Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL

PIPOZA

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

CLL2-BZAG

CLL-Frail

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

VTB-CLL002

CLL17

CLL2-BAAG

AMPLIFY

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

UK-Haplo

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)